Products
Donzakimig Biosimilar Trispecific Antibody (IL-22 × IL-13 × Albumin) for Research
Cat No.: GMP-Bios-INN-1163
Anti-IL22 therapeutic antibody (Pre-made Donzakimig biosimilar,Trispecific (G1(VH-CH1-h)-scFv_L-kappa-scFv)) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Donzakimig (development code UCB-1381) is a trispecific antibody targeting interleukin-22 (IL-22), IL-13 and albumin. It is developed by UCB Biopharma for atopic dermatitis. It is in Phase I/II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1163-1mg | 1mg | |
| GMP-Bios-INN-1163-10mg | 10mg | |
| GMP-Bios-INN-1163-100mg | 100mg | |
| GMP-Bios-INN-1163-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Donzakimig biosimilar, Trispecific (G1(VH-CH1-h)-scFv_L-kappa-scFv), Anti-IL22;ALB;IL13 Antibody: Anti-IL-21/IL-22/IL-D110/IL-TIF therapeutic antibody |
| INN Name | Donzakimig |
| Target | IL22;ALB;IL13 |
| Format | Trispecific (G1(VH-CH1-h)-scFv_L-kappa-scFv); Bispecific entry |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1;na |
| VD LC | Kappa;Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;5fuo:HL/5fuz:HL |
| 95-98% SI Structure | None;None |
| Year Proposed | 2023 |
| Year Recommended | 2024 |
| Companies | UCB Biopharma |
| Conditions Approved | na |
| Conditions Active | Atopic dermatitis |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
